Clinical trial · Observational
Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients
Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients Via Analysis of Immunoinflammation-related Protein Complexes in Blood
NCT04145947CI-TRIAL-00041721unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The relationship between immune inflammation-related protein complexes in blood of triple negative breast cancer patients and recurrence or metastasis of breast cancer will be studied.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Triple Negative Breast Cancer | Triple-Negative Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- triple negative breast cancer
- description
- triple negative breast cancer patients with age ≤ 60 years old
Primary outcomes (2)
- measure
- immune inflammation-related protein complexes
- timeFrame
- 2 years
- description
- The change of immune inflammation-related protein complexes which is measured by gel permeation chromatography.
- measure
- blood markers
- timeFrame
- 2 years
- description
- The expression of CA153, CEA, CA125 in the blood of the patients, which are measured by electro-chemiluminescence immunoassay.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 36 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Female * Postoperative pathology confirmed invasive breast cancer after surgery for breast lump * Breast cancer-related chemotherapy and radiotherapy completed * triple negative breast cancer patients * age ≤ 60 years old Exclusion Criteria: * Male * Aged above 60 * Breast Carcinoma in situ * Women in pregnancy or breastfeeding * Suffering from other malignant tumors * Non-compliant patient
References
Publications (0)
Data not yet available
No reference posted for this study.